RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement

13h ago, source:

RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel ...

RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026

3d ago, source:

RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel ...

RenovoRx Announces $11.1 Million at Market Private Placement

10d ago, source: Stockhouse

About RenovoRx, Inc. RenovoRx is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic ...

RenovoRx Receives Financing to Advance Clinical Development of Oncology Therapies

10d ago, source: Endovascular Today

RenovoRx, Inc. announced the execution of definitive subscription agreements with accredited investors for a private ...

RenovoRx Highlights Key Leadership Promotions

1mon ago, source: Nasdaq

LOS ALTOS, Calif.--(BUSINESS WIRE)-- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel ...

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

2d ago, source: Stockhouse

Sub-study of the pivotal Phase III TIGeR-PaC clinical trial offers important data to potentially assist in optimization of TAMP therapy RenovoRx, Inc. (“RenovoRx” or the “Company ...

RenovoRx Inc.

22d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Autonomix Medical Inc. Covered In Benzinga Article Highlighting Innovative Nerve Treatment Technology

2d ago, source:

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology Company is targeting pancreatic cancer pain ...

RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium

1mon ago, source: ADVFN

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced the acceptance of four clinical data abstracts ...

RenovoRx announces key leadership promotions

1mon ago, source: Investing

LOS ALTOS, Calif. – RenovoRx, Inc. (NASDAQ: RNXT), a biopharmaceutical company specializing in precision oncology therapies, has announced the promotion of two senior members to its leadership team.